Onctura commences randomized Phase I/II study in non-small cell lung cancer First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have ...

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year ...

YUTIQ addresses a significant unmet need in the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The uveitis treatment market is projected to grow steadily ...

DelveInsight's "YUTIQ Market Size, Forecast, and Market Insight Report" highlights the details around YUTIQ, a sterile ...

Many Ugandans continue to face delayed diagnoses, limited access to specialised care, and low public awareness about eye ...

HealthDay News — For patients with unresectable metastatic uveal melanoma (mUM), the drug/device combination melphalan/hepatic delivery system (HDS) is efficacious and has a favorable risk-benefit ...

Immunocore Holdings' stock has dropped 60% as Kimmtrak faces market saturation, but its pipeline could offer potential. Find out why IMCR stock is a hold.

A cancer treatment described as 'the best early Christmas present I could've asked for', has been given FDA and NICE approval.

You may want to keep an eye on the blood vessels at the back of your peepers — they could reveal if you’re likely to develop dementia. Dementia — the progressive decline in cognitive ...

FIRST ON FOX: A new transparency report looking at a popular multibillion-dollar program in the Department of Labor has found a meager success rate, setting the stage for possible cuts amid the ...

Meanwhile, another Milton Park firm has become the first to win regulatory approval for a treatment for an aggressive form of eye cancer. Immunocore’s KIMMTRAK (tebentafusp) – a treatment for patients ...